{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:59:15Z","timestamp":1778072355576,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["Grant"],"award-info":[{"award-number":["Grant"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000191","name":"Kidney Foundation of Canada","doi-asserted-by":"crossref","award":["Biomedical Grant"],"award-info":[{"award-number":["Biomedical Grant"]}],"id":[{"id":"10.13039\/501100000191","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>Atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) have been linked to mutations in many of the proteins that are involved in alternative complement pathway activation. Age and etiology confounded, the prevalence of such mutations has been reported to be over 30 to 50% in these diseases. However, the cohorts studied included many children or individuals with a familial history of complement-related disorders and genetic tests were usually limited to exome sequencing of known causative or risk-associated genes. In this study, a retrospective adult cohort of 35 patients with biopsy-proven thrombotic microangiopathy (the largest in Canada) and 10 patients with C3 glomerulopathy was tested through an extended exome panel to identify causative defects in associated or candidate genes including those of the alternative and terminal complement pathways. A variant of unknown significance was also analyzed for pathogenicity through in vitro studies. To our surprise, the prevalence of known causative or risk-associated variants in either of these cohorts was found to be less than\u2009~\u200915% overall. However, the panel used and analyses carried out allowed to identify novel variants of potential clinical significance and a number of candidate genes. The prevalence of known genetic defects in adult-onset aHUS and C3G is thus probably much lower than 30 to 50%. Our results also point towards the importance of investigating diseases of the alternative complement pathway through extended exome panels and in vitro analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key messages<\/jats:title>\n                <jats:p><jats:list list-type=\"bullet\">\n                  <jats:list-item>\n                    <jats:p>The alternative complement pathway plays a major role in the pathogenesis of hemolytic uremic syndrome and C3 glomerulopathy.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>Based on previous studies, both disorders have been commonly linked to variants in the various intermediates that sustain or regulate this pathway.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>The prevalence of such mutations in the adult-onset and sporadic forms of these diseases is probably much lower than expected based on larger series.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>The sporadic forms of complementopathies are likely to involve additional genes that are yet to be uncovered.<\/jats:p>\n                  <\/jats:list-item>\n                <\/jats:list><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00109-021-02102-1","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T04:02:41Z","timestamp":1635480161000},"page":"269-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy"],"prefix":"10.1007","volume":"100","author":[{"given":"Ludwig","family":"Haydock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre P.","family":"Garneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai-Yun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanlin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00ebl","family":"Harrisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5569-6258","authenticated-orcid":false,"given":"Paul","family":"Isenring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"issue":"10","key":"2102_CR1","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A et al (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5(10):1844\u20131859. https:\/\/doi.org\/10.2215\/CJN.02210310","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2102_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L et al (2013) Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 8(4):554\u2013562. https:\/\/doi.org\/10.2215\/CJN.04760512","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2102_CR3","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1055\/s-0030-1262886","volume":"36","author":"M Le Quintrec","year":"2010","unstructured":"Le Quintrec M, Roumenina L, Noris M, Fremeaux-Bacchi V (2010) Atypical hemolytic uremic syndrome associated with mutations in complement regulator genes. Semin Thromb Hemost 36(6):641\u2013652. https:\/\/doi.org\/10.1055\/s-0030-1262886","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2102_CR4","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s11825-018-0216-0","volume":"30","author":"WJC Feitz","year":"2018","unstructured":"Feitz WJC, van de Kar N, Orth-Holler D, van den Heuvel L, Licht C (2018) The genetics of atypical hemolytic uremic syndrome. Med Genet 30(4):400\u2013409. https:\/\/doi.org\/10.1007\/s11825-018-0216-0","journal-title":"Med Genet"},{"issue":"3","key":"2102_CR5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.molimm.2013.05.224","volume":"56","author":"EK Wong","year":"2013","unstructured":"Wong EK, Goodship TH, Kavanagh D (2013) Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 56(3):199\u2013212. https:\/\/doi.org\/10.1016\/j.molimm.2013.05.224","journal-title":"Mol Immunol"},{"issue":"11","key":"2102_CR6","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrneph.2012.195","volume":"8","author":"M Noris","year":"2012","unstructured":"Noris M, Mescia F, Remuzzi G (2012) STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 8(11):622\u2013633. https:\/\/doi.org\/10.1038\/nrneph.2012.195","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"2102_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.revmed.2009.09.039","volume":"32","author":"V Fremeaux-Bacchi","year":"2011","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C (2011) Atypical hemolytic-uremic syndrome related to abnormalities within the complement system. Rev Med Interne 32(4):232\u2013240. https:\/\/doi.org\/10.1016\/j.revmed.2009.09.039","journal-title":"Rev Med Interne"},{"issue":"4","key":"2102_CR8","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1055\/s-0034-1375701","volume":"40","author":"S Sethi","year":"2014","unstructured":"Sethi S, Fervenza FC (2014) Pathology of renal diseases associated with dysfunction of the alternative pathway of complement: C3 glomerulopathy and atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 40(4):416\u2013421. https:\/\/doi.org\/10.1055\/s-0034-1375701","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2102_CR9","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1093\/ndt\/gfn687","volume":"24","author":"SA De Serres","year":"2009","unstructured":"De Serres SA, Isenring P (2009) Athrombocytopenic thrombotic microangiopathy, a condition that could be overlooked based on current diagnostic criteria. Nephrol Dial Transplant 24(3):1048\u20131050. https:\/\/doi.org\/10.1093\/ndt\/gfn687","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2102_CR10","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00467-013-2561-1","volume":"29","author":"LS Keir","year":"2014","unstructured":"Keir LS, Saleem MA (2014) Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 29(10):1895\u20131902. https:\/\/doi.org\/10.1007\/s00467-013-2561-1","journal-title":"Pediatr Nephrol"},{"issue":"10095","key":"2102_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C (2017) Haemolytic uraemic syndrome. Lancet 390(10095):681\u2013696. https:\/\/doi.org\/10.1016\/S0140-6736(17)30062-4","journal-title":"Lancet"},{"issue":"4","key":"2102_CR12","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1055\/s-0034-1376153","volume":"40","author":"M Riedl","year":"2014","unstructured":"Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, Licht C (2014) Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 40(4):444\u2013464. https:\/\/doi.org\/10.1055\/s-0034-1376153","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"2102_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1681\/ASN.2009070706","volume":"21","author":"F Fakhouri","year":"2010","unstructured":"Fakhouri F, Roumenina L, Provot F, Sallee M, Caillard S, Couzi L, Essig M, Ribes D, Dragon-Durey MA, Bridoux F et al (2010) Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21(5):859\u2013867. https:\/\/doi.org\/10.1681\/ASN.2009070706","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2102_CR14","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN (2015) Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 125(4):616\u2013618. https:\/\/doi.org\/10.1182\/blood-2014-11-611335","journal-title":"Blood"},{"issue":"6","key":"2102_CR15","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","volume":"91","author":"S Timmermans","year":"2017","unstructured":"Timmermans S, Abdul-Hamid MA, Vanderlocht J, Damoiseaux J, Reutelingsperger CP, van Paassen P, Limburg Renal R (2017) Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities. Kidney Int 91(6):1420\u20131425. https:\/\/doi.org\/10.1016\/j.kint.2016.12.009","journal-title":"Kidney Int"},{"issue":"3","key":"2102_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S et al (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int 91(3):539\u2013551. https:\/\/doi.org\/10.1016\/j.kint.2016.10.005","journal-title":"Kidney Int"},{"issue":"3","key":"2102_CR17","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","volume":"15","author":"RJH Smith","year":"2019","unstructured":"Smith RJH, Appel GB, Blom AM, Cook HT, D\u2019Agati VD, Fakhouri F, Fremeaux-Bacchi V, Jozsi M, Kavanagh D, Lambris JD et al (2019) C3 glomerulopathy - understanding a rare complement-driven renal disease. Nat Rev Nephrol 15(3):129\u2013143. https:\/\/doi.org\/10.1038\/s41581-018-0107-2","journal-title":"Nat Rev Nephrol"},{"key":"2102_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-3989-0","author":"M Noris","year":"2018","unstructured":"Noris M, Donadelli R, Remuzzi G (2018) Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol. https:\/\/doi.org\/10.1007\/s00467-018-3989-0","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"2102_CR19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/ki.2013.377","volume":"84","author":"MC Pickering","year":"2013","unstructured":"Pickering MC, D\u2019Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, Alpers CE, Bajema IM, Bedrosian C, Braun M et al (2013) C3 glomerulopathy: consensus report. Kidney Int 84(6):1079\u20131089. https:\/\/doi.org\/10.1038\/ki.2013.377","journal-title":"Kidney Int"},{"issue":"1","key":"2102_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.molimm.2015.03.012","volume":"67","author":"PF Zipfel","year":"2015","unstructured":"Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, Fremeaux-Bacchi V, Nester C, de Cordoba SR, Noris M et al (2015) The role of complement in C3 glomerulopathy. Mol Immunol 67(1):21\u201330. https:\/\/doi.org\/10.1016\/j.molimm.2015.03.012","journal-title":"Mol Immunol"},{"issue":"8","key":"2102_CR21","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","volume":"93","author":"A Ravindran","year":"2018","unstructured":"Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S (2018) C3 Glomerulopathy: ten years\u2019 experience at Mayo Clinic. Mayo Clin Proc 93(8):991\u20131008. https:\/\/doi.org\/10.1016\/j.mayocp.2018.05.019","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2102_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/j.semdp.2020.01.002","volume":"37","author":"AJ Gallan","year":"2020","unstructured":"Gallan AJ, Chang A (2020) A new paradigm for renal thrombotic microangiopathy. Semin Diagn Pathol 37(3):121\u2013126. https:\/\/doi.org\/10.1053\/j.semdp.2020.01.002","journal-title":"Semin Diagn Pathol"},{"issue":"3","key":"2102_CR23","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.15171\/jnp.2019.27","volume":"8","author":"M Ernandes Neto","year":"2019","unstructured":"Ernandes Neto M, Soler LdM, Gallindo Vasconcelos HV, dos Santos DC, Viero RM, Gustavo de Andrade LM (2019) Histopathological features of thrombotic microangiopathies in renal biopsies. J Nephropathol 8(3):e27\u2013e27. https:\/\/doi.org\/10.15171\/jnp.2019.27","journal-title":"J Nephropathol"},{"issue":"6","key":"2102_CR24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.kint.2017.02.025","volume":"91","author":"S Van Laecke","year":"2017","unstructured":"Van Laecke S, Van Biesen W (2017) Severe hypertension with renal thrombotic microangiopathy: what happened to the usual suspect? Kidney Int 91(6):1271\u20131274. https:\/\/doi.org\/10.1016\/j.kint.2017.02.025","journal-title":"Kidney Int"},{"issue":"4","key":"2102_CR25","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jash.2015.12.007","volume":"10","author":"RO Mathew","year":"2016","unstructured":"Mathew RO, Nayer A, Asif A (2016) The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy. J Am Soc Hypertens 10(4):352\u2013359. https:\/\/doi.org\/10.1016\/j.jash.2015.12.007","journal-title":"J Am Soc Hypertens"},{"issue":"3","key":"2102_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00439-020-02216-5","volume":"140","author":"CY Lee","year":"2021","unstructured":"Lee CY, Yen HY, Zhong AW, Gao H (2021) Resolving misalignment interference for NGS-based clinical diagnostics. Hum Genet 140(3):477\u2013492. https:\/\/doi.org\/10.1007\/s00439-020-02216-5","journal-title":"Hum Genet"},{"issue":"6","key":"2102_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jmoldx.2017.07.004","volume":"19","author":"J Kerkhof","year":"2017","unstructured":"Kerkhof J, Schenkel LC, Reilly J, McRobbie S, Aref-Eshghi E, Stuart A, Rupar CA, Adams P, Hegele RA, Lin H et al (2017) Clinical validation of copy number variant detection from targeted next-generation sequencing panels. J Mol Diagn 19(6):905\u2013920. https:\/\/doi.org\/10.1016\/j.jmoldx.2017.07.004","journal-title":"J Mol Diagn"},{"issue":"Suppl 11","key":"2102_CR28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-2105-14-S11-S1","volume":"14","author":"M Zhao","year":"2013","unstructured":"Zhao M, Wang Q, Wang Q, Jia P, Zhao Z (2013) Computational tools for copy number variation (CNV) detection using next-generation sequencing data: features and perspectives. BMC Bioinformatics 14(Suppl 11):S1. https:\/\/doi.org\/10.1186\/1471-2105-14-S11-S1","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"2102_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41431-020-0672-2","volume":"29","author":"K Cassinari","year":"2021","unstructured":"Cassinari K, Coutant S, Lecoquierre F, Le Guennec K, Rousseau S, Richard AC, Vasseur S, Bouvignies E, Bou J, Lienard G et al (2021) Detection of copy-number variations from NGS data using read depth information: a diagnostic performance evaluation. Eur J Hum Genet 29(1):99\u2013109. https:\/\/doi.org\/10.1038\/s41431-020-0672-2","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"2102_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1681\/ASN.2013050453","volume":"25","author":"F Bu","year":"2014","unstructured":"Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, Smith RJ (2014) Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 25(1):55\u201364. https:\/\/doi.org\/10.1681\/ASN.2013050453","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2102_CR31","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a000828","volume":"2","author":"E Leinoe","year":"2016","unstructured":"Leinoe E, Nielsen OJ, Jonson L, Rossing M (2016) Whole-exome sequencing of a patient with severe and complex hemostatic abnormalities reveals a possible contributing frameshift mutation in C3AR1. Cold Spring Harb Mol Case Stud 2(4):a000828. https:\/\/doi.org\/10.1101\/mcs.a000828","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"8","key":"2102_CR32","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1681\/ASN.2010080795","volume":"22","author":"MA Abrera-Abeleda","year":"2011","unstructured":"Abrera-Abeleda MA, Nishimura C, Frees K, Jones M, Maga T, Katz LM, Zhang Y, Smith RJ (2011) Allelic variants of complement genes associated with dense deposit disease. J Am Soc Nephrol 22(8):1551\u20131559. https:\/\/doi.org\/10.1681\/ASN.2010080795","journal-title":"J Am Soc Nephrol"},{"key":"2102_CR33","unstructured":"Challis RC (2015) Genetics of atypical haemolytic uraemic syndrome:. PhD Thesis, Newcastle University (UK). https:\/\/theses.ncl.ac.uk\/jspui\/handle\/10443\/3080"},{"key":"2102_CR34","unstructured":"Richardson LC (2017) Defects in sialylation cause glomerular injury. Master of Science University of Toronto (Canada). ProQuest Dissertations Publishing. https:\/\/www.proquest.com\/openview\/aa32ecfd386f9bc009bf54e0b3e08caa\/1?pq-origsite=gscholar&cbl=18750&diss=y"},{"issue":"4","key":"2102_CR35","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1681\/ASN.2015101189","volume":"28","author":"RC Challis","year":"2017","unstructured":"Challis RC, Ring T, Xu Y, Wong EK, Flossmann O, Roberts IS, Ahmed S, Wetherall M, Salkus G, Brocklebank V et al (2017) Thrombotic microangiopathy in inverted formin 2-mediated renal disease. J Am Soc Nephrol 28(4):1084\u20131091. https:\/\/doi.org\/10.1681\/ASN.2015101189","journal-title":"J Am Soc Nephrol"},{"key":"2102_CR36","unstructured":"Watanabe HGSY, H.; Yamamoto, T.; Narita, I. (2014) Exome sequencing identified novel mutations of FKRP in familial atypical hemolytic uremic syndrome. J Am Soc Nephrol 25 - Abstract Supplement (Kidney Week 2014, 13.11.14 2014 Philadelphia, PA, USA. American Society of Nephrology):173A"},{"issue":"5","key":"2102_CR37","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30","journal-title":"Genet Med"},{"key":"2102_CR38","doi-asserted-by":"crossref","unstructured":"Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ (2014) New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 34 (5). 10.1042\/BSR20140117","DOI":"10.1042\/BSR20140117"},{"issue":"6","key":"2102_CR39","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","volume":"95","author":"A Le Clech","year":"2019","unstructured":"Le Clech A, Simon-Tillaux N, Provot F, Delmas Y, Vieira-Martins P, Limou S, Halimi JM, Le Quintrec M, Lebourg L, Grange S et al (2019) Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int 95(6):1443\u20131452. https:\/\/doi.org\/10.1016\/j.kint.2019.01.023","journal-title":"Kidney Int"},{"issue":"3","key":"2102_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1681\/ASN.2012090884","volume":"24","author":"E Bresin","year":"2013","unstructured":"Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D et al (2013) Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24(3):475\u2013486. https:\/\/doi.org\/10.1681\/ASN.2012090884","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2102_CR41","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1681\/ASN.2018090909","volume":"30","author":"S Cameron-Christie","year":"2019","unstructured":"Cameron-Christie S, Wolock CJ, Groopman E, Petrovski S, Kamalakaran S, Povysil G, Vitsios D, Zhang M, Fleckner J, March RE et al (2019) Exome-based rare-variant analyses in CKD. J Am Soc Nephrol 30(6):1109\u20131122. https:\/\/doi.org\/10.1681\/ASN.2018090909","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2102_CR42","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1806891","volume":"380","author":"EE Groopman","year":"2019","unstructured":"Groopman EE, Marasa M, Cameron-Christie S, Petrovski S, Aggarwal VS, Milo-Rasouly H, Li Y, Zhang J, Nestor J, Krithivasan P et al (2019) Diagnostic utility of exome sequencing for kidney disease. N Engl J Med 380(2):142\u2013151. https:\/\/doi.org\/10.1056\/NEJMoa1806891","journal-title":"N Engl J Med"},{"issue":"1","key":"2102_CR43","doi-asserted-by":"publisher","first-page":"11","DOI":"10.7326\/M18-1241","volume":"170","author":"HM Rasouly","year":"2019","unstructured":"Rasouly HM, Groopman EE, Heyman-Kantor R, Fasel DA, Mitrotti A, Westland R, Bier L, Weng C, Ren Z, Copeland B et al (2019) The burden of candidate pathogenic variants for kidney and genitourinary disorders emerging from exome sequencing. Ann Intern Med 170(1):11\u201321. https:\/\/doi.org\/10.7326\/M18-1241","journal-title":"Ann Intern Med"},{"issue":"7","key":"2102_CR44","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","volume":"200","author":"AJ Osborne","year":"2018","unstructured":"Osborne AJ, Breno M, Borsa NG, Bu F, Fremeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S et al (2018) Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy. J Immunol 200(7):2464\u20132478. https:\/\/doi.org\/10.4049\/jimmunol.1701695","journal-title":"J Immunol"},{"issue":"3","key":"2102_CR45","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/modpathol.2017.154","volume":"31","author":"CP Larsen","year":"2018","unstructured":"Larsen CP, Wilson JD, Best-Rocha A, Beggs ML, Hennigar RA (2018) Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy. Mod Pathol 31(3):488\u2013494. https:\/\/doi.org\/10.1038\/modpathol.2017.154","journal-title":"Mod Pathol"},{"issue":"3","key":"2102_CR46","doi-asserted-by":"publisher","first-page":"H349","DOI":"10.1152\/ajpheart.00759.2016","volume":"312","author":"UO Wenzel","year":"2017","unstructured":"Wenzel UO, Bode M, Kohl J, Ehmke H (2017) A pathogenic role of complement in arterial hypertension and hypertensive end organ damage. Am J Physiol Heart Circ Physiol 312(3):H349\u2013H354. https:\/\/doi.org\/10.1152\/ajpheart.00759.2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"2102_CR47","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-2006-939767","volume":"32","author":"LB Zimmerhackl","year":"2006","unstructured":"Zimmerhackl LB, Besbas N, Jungraithmayr TT, van de Kar N, Karch HH, Karpman D, Landau D, Loirat C, Proesmans W, Prufer F et al (2006) Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome. Semin Thromb Hemost 32(2):113\u2013120. https:\/\/doi.org\/10.1055\/s-2006-939767","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2102_CR48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1055\/s-2001-15247","volume":"27","author":"CM Taylor","year":"2001","unstructured":"Taylor CM (2001) Hemolytic-uremic syndrome and complement factor H deficiency: clinical aspects. Semin Thromb Hemost 27(3):185\u2013190. https:\/\/doi.org\/10.1055\/s-2001-15247","journal-title":"Semin Thromb Hemost"},{"issue":"4","key":"2102_CR49","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0034-1375296","volume":"40","author":"S Rodriguez de Cordoba","year":"2014","unstructured":"Rodriguez de Cordoba S, Hidalgo MS, Pinto S, Tortajada A (2014) Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 40(4):422\u2013430. https:\/\/doi.org\/10.1055\/s-0034-1375296","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"2102_CR50","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","volume":"3","author":"PF Zipfel","year":"2007","unstructured":"Zipfel PF, Edey M, Heinen S, Jozsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE et al (2007) Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 3(3):e41. https:\/\/doi.org\/10.1371\/journal.pgen.0030041","journal-title":"PLoS Genet"},{"issue":"2","key":"2102_CR51","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1681\/ASN.2019050515","volume":"31","author":"PF Zipfel","year":"2020","unstructured":"Zipfel PF, Wiech T, Stea ED, Skerka C (2020) CFHR gene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy. J Am Soc Nephrol 31(2):241\u2013256. https:\/\/doi.org\/10.1681\/ASN.2019050515","journal-title":"J Am Soc Nephrol"},{"issue":"24","key":"2102_CR52","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1093\/hmg\/ddg363","volume":"12","author":"J Caprioli","year":"2003","unstructured":"Caprioli J, Castelletti F, Bucchioni S, Bettinaglio P, Bresin E, Pianetti G, Gamba S, Brioschi S, Daina E, Remuzzi G et al (2003) Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 12(24):3385\u20133395. https:\/\/doi.org\/10.1093\/hmg\/ddg363","journal-title":"Hum Mol Genet"},{"issue":"6","key":"2102_CR53","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh D, Goodship TH, Richards A (2013) Atypical hemolytic uremic syndrome. Semin Nephrol 33(6):508\u2013530. https:\/\/doi.org\/10.1016\/j.semnephrol.2013.08.003","journal-title":"Semin Nephrol"},{"key":"2102_CR54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1750-1172-6-60","volume":"6","author":"C Loirat","year":"2011","unstructured":"Loirat C, Fremeaux-Bacchi V (2011) Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 6:60. https:\/\/doi.org\/10.1186\/1750-1172-6-60","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2102_CR55","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.molimm.2011.11.003","volume":"49","author":"L Ermini","year":"2012","unstructured":"Ermini L, Goodship TH, Strain L, Weale ME, Sacks SH, Cordell HJ, Fremeaux-Bacchi V, Sheerin NS (2012) Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol 49(4):640\u2013648. https:\/\/doi.org\/10.1016\/j.molimm.2011.11.003","journal-title":"Mol Immunol"},{"issue":"6","key":"2102_CR56","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1084\/jem.20070301","volume":"204","author":"MC Pickering","year":"2007","unstructured":"Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, Moss J, Walport MJ, Cook HT, de Cordoba SR et al (2007) Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 204(6):1249\u20131256. https:\/\/doi.org\/10.1084\/jem.20070301","journal-title":"J Exp Med"},{"issue":"5","key":"2102_CR57","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/hmg\/ddi066","volume":"14","author":"J Esparza-Gordillo","year":"2005","unstructured":"Esparza-Gordillo J, Goicoechea de Jorge E, Buil A, Carreras Berges L, Lopez-Trascasa M, Sanchez-Corral P, Rodriguez de Cordoba S (2005) Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 14(5):703\u2013712. https:\/\/doi.org\/10.1093\/hmg\/ddi066","journal-title":"Hum Mol Genet"},{"key":"2102_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-021-00424-4","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fremeaux-Bacchi V (2021) Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol. https:\/\/doi.org\/10.1038\/s41581-021-00424-4","journal-title":"Nat Rev Nephrol"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-021-02102-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-021-02102-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T08:04:52Z","timestamp":1642579492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-021-02102-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2102"],"URL":"https:\/\/doi.org\/10.1007\/s00109-021-02102-1","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]},"assertion":[{"value":"2 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval has been obtained by the CHU de Qu\u00e9bec. Signed agreement to participate has also been obtained by the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Signed agreement to participate has been obtained by the patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}